147 related articles for article (PubMed ID: 8993510)
1. Preclinical antitumor activity and pharmacokinetics of irinotecan (CPT-11) in tumor-bearing mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Ann N Y Acad Sci; 1996 Dec; 803():173-80. PubMed ID: 8993510
[No Abstract] [Full Text] [Related]
2. A review of the clinical experience with irinotecan (CPT-11).
Horowitz RW; Wadler S; Wiernik PH
Am J Ther; 1997; 4(5-6):203-10. PubMed ID: 10423612
[TBL] [Abstract][Full Text] [Related]
3. [CPT-11: new drug for metastatic colorectal cancer].
Barone C; Pozzo C; Cassano A
Tumori; 1999; 85(6):A1-11. PubMed ID: 10774581
[No Abstract] [Full Text] [Related]
4. Design, synthesis and development of novel camptothecin drugs.
Liew ST; Yang LX
Curr Pharm Des; 2008; 14(11):1078-97. PubMed ID: 18473856
[TBL] [Abstract][Full Text] [Related]
5. Insights into the pharmacokinetics and pharmacodynamics of irinotecan.
Ratain MJ
Clin Cancer Res; 2000 Sep; 6(9):3393-4. PubMed ID: 10999719
[No Abstract] [Full Text] [Related]
6. [Pharmacokinetics and tissue distribution of irinotecan hydrochloride nanoparticles].
Yang FY; Zhang WP; Chen HL; Fu Y; Wang XY; Wei SJ; Yang XY; Zhang YX; Dang HW
Yao Xue Xue Bao; 2013 Jun; 48(6):940-5. PubMed ID: 23984532
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology and pharmacodynamics of irinotecan. A review.
Chabot GG
Ann N Y Acad Sci; 1996 Dec; 803():164-72. PubMed ID: 8993509
[No Abstract] [Full Text] [Related]
8. Oral versus intraperitoneal administration of irinotecan in the treatment of human neuroblastoma in nude mice.
Choi SH; Tsuchida Y; Yang HW
Cancer Lett; 1998 Feb; 124(1):15-21. PubMed ID: 9500186
[TBL] [Abstract][Full Text] [Related]
9. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion.
Ohe Y; Sasaki Y; Shinkai T; Eguchi K; Tamura T; Kojima A; Kunikane H; Okamoto H; Karato A; Ohmatsu H
J Natl Cancer Inst; 1992 Jun; 84(12):972-4. PubMed ID: 1321253
[No Abstract] [Full Text] [Related]
10. Cell kinetics-dependent antitumor effect of irinotecan hydrochloride induced by the synchronizing effect of hydroxyurea: cell kinetics and dosing time.
Akagi T; Ushinohama K; Kage Y; Ishizaki T; Makinosumi T; Yamauchi A; Taguchi Y; Inoue K; Yukawa E; Higuchi S; Ohdo S
Life Sci; 2003 Jan; 72(10):1183-97. PubMed ID: 12505548
[TBL] [Abstract][Full Text] [Related]
11. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11.
Sadzuka Y; Hirotsu S; Hirota S
Cancer Lett; 1998 May; 127(1-2):99-106. PubMed ID: 9619864
[TBL] [Abstract][Full Text] [Related]
12. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts.
Zamboni WC; Houghton PJ; Thompson J; Cheshire PJ; Hanna SK; Richmond LB; Lou X; Stewart CF
Clin Cancer Res; 1998 Feb; 4(2):455-62. PubMed ID: 9516936
[TBL] [Abstract][Full Text] [Related]
13. Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice.
Morton CL; Iacono L; Hyatt JL; Taylor KR; Cheshire PJ; Houghton PJ; Danks MK; Stewart CF; Potter PM
Cancer Chemother Pharmacol; 2005 Dec; 56(6):629-36. PubMed ID: 15918039
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of irinotecan and its metabolites.
Siderov J
J Clin Oncol; 2002 Dec; 20(23):4609; author reply 4609-10. PubMed ID: 12454126
[No Abstract] [Full Text] [Related]
15. Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.
Mross K; Steinbild S; Baas F; Reil M; Buss P; Mersmann S; Voliotis D; Schwartz B; Brendel E
Int J Clin Pharmacol Ther; 2003 Dec; 41(12):618-9. PubMed ID: 14692719
[No Abstract] [Full Text] [Related]
16. [CPT-11 (irinotecan)--evidence from molecular and pharmacological studies and clinical applications].
Isobe T; Ishikawa N; Oguri T
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1267-78. PubMed ID: 10945026
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"?
Ratain MJ
J Clin Oncol; 2002 Jan; 20(1):7-8. PubMed ID: 11773147
[No Abstract] [Full Text] [Related]
18. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo.
Yu D; Peng P; Dharap SS; Wang Y; Mehlig M; Chandna P; Zhao H; Filpula D; Yang K; Borowski V; Borchard G; Zhang Z; Minko T
J Control Release; 2005 Dec; 110(1):90-102. PubMed ID: 16271793
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of CPT-11 and its active metabolite SN-38.
Lavelle F; Bissery MC; André S; Roquet F; Riou JF
Semin Oncol; 1996 Feb; 23(1 Suppl 3):11-20. PubMed ID: 8633248
[TBL] [Abstract][Full Text] [Related]
20. Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization.
Rose WC; Marathe PH; Jang GR; Monticello TM; Balasubramanian BN; Long B; Fairchild CR; Wall ME; Wani MC
Cancer Chemother Pharmacol; 2006 Jul; 58(1):73-85. PubMed ID: 16228206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]